Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma

NCT03478514 is registered in ClinicalTrials.gov with Alliance Foundation Trials, LLC. as lead sponsor.

NCT NCT03478514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03478514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Lead sponsor
Alliance Foundation Trials, LLC.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 11, 2018
Completion date
July 30, 2027
Enrollment
39 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

b cell lymphoma, mantle cell lymphoma